Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Women with relapsed high-grade serous ovarian cancer can participate if they:
Participants are excluded if they:
For information about the study, contact the AstraZeneca Clinical Study Information Center by phone: 1-877-240-9479 or by email.
This study will look at olaparib (Lynparza) tablets as a treatment for relapsed ovarian cancer in women with, or without a BRCA mutation. Patients should have received at least 2 prior lines of platinum-based chemotherapy. All participants will receive the study agent, olaparib.
The study goal is to compare response to treatment based on whether women have an inherited BRCA mutation or BRCA-like cancer based on tumor tests.
Visit the study listing on clinicaltrials.gov for more information.
This is a nonrandomized, open label study. All participants will receive the study agent, olaparib. This study is comparing response to treatment in four different grousp of patients. The study is non-randomized, meaning that patients will be assigned to one of four groups based on specifics of their cancer. All patients in the study will receive olaparib.
All patients enrolled in the study will receive the study agent, olaparib. Patients will take olaparib pills twice daily while on the study.
Olaparib belongs to a category of drugs known as PARP inhibitors. These agents have shown benefit for treating ovarian cancer in women with inherited BRCA mutations. The drugs also show benefit for patients who do not have a BRCA mutation. The study goal is to compare response to treatment in four different groups of ovarian cancer patients to see which patients benefit most from this drug.
The study is open in many locations in the US. For all sites, contact the AstraZeneca Clinical Study Information Center by phone at: 1-877-240-9479 or by email.